Analysis and prevention of adverse responses to drugs used in dentistry

Cover Page

Cite item

Full Text

Abstract

Drug preparations, a substance or a mixture of substances of synthetic or natural origin, are used for the prevention, diagnosis, and treatment of various diseases. Along with the benefits, drug prepararions can also have adverse side effects, identifying the causes of which is quite problematic in the practice of a dentist because of the diversity of the clinical picture. The rational use and optimal choice of a drug among a wide range of drugs depend on the profile of its effectiveness and safety, drug interaction, individual characteristics of the patient (genetic polymorphism), and other concomitant diseases. Nowadays, the practice of a dentist is impossible to imagine without the use of drugs. Drug preparations allow doctors providing quality medical care that meets international standards, but do not forget that when prescribing a drug is extremely important to consider how rationally and necessary to use it to achieve a positive result in treatment. Therefore, the study of the prevention of the development of unwanted adverse reactions of drugs in dentistry is an important topic that requires close attention. Based on the analysis of the literature on the RSCI, Scopus, Web of Science, MedLine databases, the most commonly prescribed groups of drugs in dentistry were found to be as follows: non-steroidal anti-inflammatory drugs (NSAIDs), topically anesthetizing, antimicrobial, antiseptic, and drugs. The aim of the study: On the basis of the analysis of modern information about undesirable reactions of drugs, often used in dentistry, to optimize approaches to rational use and prevention of undesirable side effects.

About the authors

Natalia N. Vlasova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: vlasova12345@yandex.ru
ORCID iD: 0000-0003-3665-1916

MD, Ph.D., Associate professor, Department of the therapeutic dentistry оf the I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, 119991, Russian Federation.

e-mail: vlasova12345@yandex.ru

Russian Federation

S. S. Sologova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: noemail@neicon.ru
ORCID iD: 0000-0002-8526-7147
Russian Federation

O. I. Tereshkina

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: noemail@neicon.ru
ORCID iD: 0000-0001-7434-9481
Russian Federation

I. A. Sochova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: noemail@neicon.ru
ORCID iD: 0000-0002-1569-8080
Russian Federation

V. N. Chubarev

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: noemail@neicon.ru
ORCID iD: 0000-0002-7047-1436
Russian Federation

N. I. Prokhorov

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: noemail@neicon.ru
ORCID iD: 0000-0002-4510-2890
Russian Federation

D. I. Sologova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: noemail@neicon.ru
ORCID iD: 0000-0002-6376-7802
Russian Federation

References

  1. Астахова А.В., Лепахин В.К. Лекарства. Неблагоприятные побочные реакции и контроль безопасности. М.: Эксмо; 2008. 200 с.
  2. Журавлева М.В., Романов Б.К., Городецкая Г.И., Муслимова О.В., Крысанова В.С., Демченкова Е.Ю. Актуальные вопросы безопасности лекарственных средств, возможности совершенствования системы фармаконадзора. Безопасность и риск фармакотерапии. 2019; 7 (3): 109-19. https://doi.org/10.30895/2312-7821-2019-7-3-109-119
  3. Дмитриева Л.А., Максимовский Ю.М., ред. Терапевтическая стоматология: национальное руководство. М.: ГЭОТАР-Медиа; 2009. 912 с.
  4. Свистунов А.А., Тарасов В.В., ред. Фармакология: учебник для студентов стоматологических факультетов. М.: Лаборатория знаний; 2018. 352 с.
  5. Tripathi K.D. Essentials of Pharmacology for Dentistry. 3rd еd. New Delhi: Jaypee Brothers Med. Publ.; 2016.
  6. Krasniqi V., Dimovski A., Domjanović I.K., Bilić I., Božina N. How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity. Arh Hig Rada Toksikol. 2016; 67: 1-8. https://doi.org/10.1515/aiht-2016-67-2754
  7. Nies A.T., Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch. 2007; 453: 643-59. https://doi.org/10.1007/s00424-006-0109-y
  8. Johansson I., Ingelman-Sundberg M. Genetic polymorphismand toxicology - with emphasis on Cytochrome p450. Toxicol Sci. 2011; 120: 1-13. https://doi.org/10.1093/toxsci/kfq374/]
  9. Кукес В.Г., Сычев Д.А., ред. Клиническая фармакология: учебник. 5-е изд., испр. и доп. М.: ГЭОТАР-Медиа; 2017. 1024 с
  10. Božina N., Bradamante V., Lovrić M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity and cancer risk. Arh Hig Rada Toksikol. 2009; 60: 217-42. https://doi.org/10.2478/10004-1254-60-2009-1885
  11. Sim S.C., Kacevska M., Ingelman-Sundberg M. Pharmaco genomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J. 2013; 13: 1-11. https://doi.org/10.1038/tpj.2012.45
  12. Lanas A., García-Rodríguez L.A., Arroyo M.T., Gomollón F., Feu F., González-Pérez A. et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006; 55: 1731-8. https://doi.org/10.1136/gut.2005.080754
  13. Ishihara M., Ohmiya N., Nakamura M., Funasaka K., Miyahara R., Ohno E. et al. Risk factors of symptomatic NSAID-induced small intestinal injury and diaphragm disease. Aliment Pharmacol Ther. 2014; 40: 538-47. https://doi.org/10.1111/apt.12858
  14. Johansson I.0., Ingelman-Sundberg M. Genetic polymorphism and toxicology - with emphasis on Cytochrome P450. Toxicol Sci. 2011; 120 (1): 1-13. https://doi.org/10.1093/toxsci/kfq374
  15. Lagas J.S., Sparidans R.W., Wagenaar E., Beijnen J.H., Schinkel AH. Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters. Mol Pharmacol. 2010; 77 (4): 687-94. https://doi.org/10.1124/mol.109.062364
  16. Stamer U.M., Zhang L., Stuber F. Personalized therapy in pain management: where do we stand? Pharmacogenomics. 2010; 11 (6): 843-64. https://doi.org/10.2217/pgs.10.47
  17. Луцкая И.К., Мартов В.Ю. Лекарственные средства в стоматологии. М.: МедЛит; 2018. 384 с
  18. Zi J., Liu D., Ma P., Huang H., Zhu J., Wei D. et al. Effects of CYP2C9*3 and CYP2C9*13 on diclofenac-metabolism and inhibition-based drug-drug interactions. Drug Metab Pharmacokinet. 2010; 25 (4): 343-350.
  19. Piccinni C., Gissi D.B., Gabusi A., Montebugnoli L., Poluzzi E. Paraesthesia after local anaesthetics: an analysis of reports to the FDA Adverse Event Reporting System. Basic Clin Pharmacol Toxicol. 2015; 117: 52-6. https://doi.org/10.1111/bcpt.12357
  20. Haas D.A. Localized complications from local anesthesia. J Calif Dent Assoc.1998; 26: 677-82.
  21. Haas D.A. Articaine and paresthesia: epidemiological studies. J Am Coll Dent. 2006; 73: 5-10.
  22. Paxton M.C., Hadley J.N., Hadley M.N., Edwards R.C., Harrison S.J. Chorda tympani nerve injury following inferior alveolar injection: a review of two cases. J Am Dent Assoc. 1994; 125: 1003-6.
  23. Pogrel M.A. Permanent nerve damage from inferior alveolar nerve blocks: a current update. J Calif Dent Assoc. 2012; 40 (10): 795-7.
  24. Gaffen A.S., Haas D.A. Retrospective review of voluntary reports of nonsurgical paresthesia in dentistry. J Can Dent Assoc. 2009; 75 (8): 579.
  25. Garisto G.A., Gaffen A.S., Lawrence H.P., Tenenbaum H.C., Haas D.A. Occurrence of paresthesia after dental local anesthetic administration in the United States. J Am Dent Assoc. 2010; 141 (7): 836-44.
  26. Фассахов Р.С., Решетникова И.Д., Войцехович Г.С., Макарова Л.В., Горшунова Н.А. Анафилактический шок: причины, клинические проявления, неотложная терапия, профилактика. Практическая медицина. 2009; (5).
  27. Хохлова З.А., Гилёва Р.А., Коняхина И.Г., Тишкина А.П. Синдром Лайелла. Случай из практики. Архивъ внутренней медицины. 2018; (3): 231-6. https://doi.org/10.20514/2226-6704-2018-8-3-231-236
  28. Федеральные клинические рекомендации по ведению больных синдромом Стивенса-Джонсона/токсическим эпидермальным некролизом. Российское общество дерматовенерологов и косметологов. М.; 2015. 11 с.
  29. Тезяева С.А., Млинник Р.А., Дегтярева С.Ф. и соавт. Синдром Лайелла как редкое осложнение медикаментозной терапии (клинические случаи). Медиаль. 2015; 2 (16): 42-5.
  30. Васильчикова И.И. Лекарственная аллергия. (Клинический случай синдрома Стивенса-Джонсона). Астма и аллергия. 2015; 1 (5): 35-9.
  31. Mahboob A., Haroon T.S., Drugs causing fixed erutrions: a study of 450 cases. Int J Detmatol. 1998; 37: 833-8. https://doi.org/10.1046/j.1365-4362.1998.00451.x
  32. Rafal’skij V.V. Undesirable drug reactions and interactions with antibiotic therapy of urinary tract infections. Russkiy Meditsinskiy Zhurnal. 2000; 3: 110. (in Russian)
  33. Taqi SA. Drug-induced oral erythema multiforme: A diagnostic challenge. Ann Afr Med. 2018; 17 (1): 43-5. https://doi.org/10.4103/aam.aam_19_17
  34. Medvedeva M.B. Treatment of acute forms of candidiasis of the oral mucosa in young people. Vіsnik VDNZU Ukraїns›koї medichnoї stomatologіchnoї akademії. Aktual›nі problemi suchasnoї medicine. 2011; 11 (4): 19-23. (in Russian)
  35. Sychev D.A., Otdelenov V.A., eds. Polypharmacy in clinical practice: a problem and solutions: a training manual. SPb.: TsOP Professiya; 2016. 224 p. (in Russian)

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Vlasova N.N., Sologova S.S., Tereshkina O.I., Sochova I.A., Chubarev V.N., Prokhorov N.I., Sologova D.I.


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 37884 от 02.10.2009.